Does statin therapy reduce incidence of stroke? A meta-analysis;Les statines préviennent-elles le risque d' accident vasculaire cérébral? Méta-analyse

Annales de Medecine Interne

Volumn 152, Issue 3, 2001, Pages 188-193

  Sirol, M ^a   Bouzamondo, A ^a   Sanchez, P ^a   Lechat, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Meta analysis; Statines; Stroke

Indexed keywords

PLACEBO; PRAVASTATIN; SIMVASTATIN; STATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PROPHYLAXIS; RISK; SECONDARY PREVENTION; STROKE;

AGE DISTRIBUTION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; EFFECT MODIFIERS (EPIDEMIOLOGY); HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PRAVASTATIN; PRIMARY PREVENTION; RISK; RISK FACTORS; SIMVASTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034942113     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Incidence of transient ischemic attacks in Dijon, France. A 5-year community-based study
2. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
3. Blood pressure, cholesterol, and stroke in Eastern Asia
4. American Heart Association Prevention Conference. IV-Prevention and rehabilitation of stroke. Risk factors
5. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials
6. PSC, cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration
7. An overview of trials of cholesterol lowering and risk of stroke
8. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study
9. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial (MRFIT)
10. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
11. Effect of cholesterol lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and the risk of stroke
12. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries
13. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy
14. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review
15. ACAPS: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
16. WOSCOPS: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
17. 4S, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
18. CARE: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. TLSG, prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
20. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
21. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
22. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
23. HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data
24. Effect of HMG-coA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials
25. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/liter (200 to 300mg/dl) plus two additional atherosclerotic risk factors
26. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
27. MARS: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)
28. PLAC I: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation
29. REGRESS: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
30. LRT: Lack of effect of lovastatin on restenosis after coronary angioplasty
31. MIRACL: Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
32. (4S), Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
33. Vascular effects of statins in stroke
34. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
35. Total cholesterol and risk of mortality in the oldest old